Table 4.
Pharmacokinetic parameters of megestrol acetate solid dispersion nanoparticles prepared using the SAS process
| AUC0–24(ng·h/mL) | Cmax (ng/mL) | Tmax (hours) | |
|---|---|---|---|
| Raw megestrol acetate | 2,029.7±407.5 | 234.8±42.5 | 2.0±0.6 |
| Drug:HPMC =1:2 | 5,305.6±1,172.3a | 805.7±82.5a | 1.1±0.4 |
| Drug:HPMC:Ryoto sugar ester L1695 =1:2:1 | 8,175.9±1,130.1a,b | 1,288.2±198.0a,b | 1.0±0.4 |
Notes:
a
P<0.05 versus raw megestrol acetate;
b
P<0.05 versus drug:HPMC =1:2. Data expressed as mean ± standard deviation (n=5).
Abbreviations: SAS, supercritical antisolvent; AUC, area under the concentration–time curve; Cmax, peak plasma concentration; Tmax, time to Cmax; HPMC, hydroxypropylmethyl cellulose.